Stevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Stevanato Group S.p.A. (NYSE:STVN) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company.

Several equities analysts have recently weighed in on STVN shares. Wolfe Research started coverage on Stevanato Group in a research report on Tuesday. They issued an “outperform” rating and a $21.00 price target for the company. Jefferies Financial Group set a $17.50 price target on Stevanato Group in a research report on Tuesday, February 10th. Morgan Stanley reduced their price target on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Weiss Ratings cut Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 11th. Finally, Wall Street Zen cut Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th.

Hedge Funds Weigh In On Stevanato Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Wyoming grew its position in Stevanato Group by 39,216.7% during the second quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after buying an additional 2,353 shares in the last quarter. GW&K Investment Management LLC grew its position in Stevanato Group by 76.2% during the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after buying an additional 1,055 shares in the last quarter. Quantbot Technologies LP purchased a new position in Stevanato Group during the third quarter worth about $68,000. Van Berkom & Associates Inc. grew its position in Stevanato Group by 50.6% during the third quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company’s stock worth $93,000 after buying an additional 1,215 shares in the last quarter. Finally, Fifth Third Bancorp grew its position in Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after buying an additional 773 shares in the last quarter.

Stevanato Group Price Performance

Shares of NYSE STVN opened at €18.92 on Friday. The stock has a market cap of $5.73 billion, a PE ratio of 32.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.78. Stevanato Group has a fifty-two week low of €12.89 and a fifty-two week high of €28.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The stock has a fifty day moving average of €16.08 and a 200-day moving average of €17.88.

Stevanato Group (NYSE:STVN) last announced its quarterly earnings results on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing the consensus estimate of €0.12 by (€0.01). The company had revenue of €273.57 million during the quarter. Stevanato Group had a net margin of 11.76% and a return on equity of 10.27%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. Equities research analysts anticipate that Stevanato Group will post 0.68 earnings per share for the current year.

Stevanato Group Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Wednesday, July 29th. Investors of record on Thursday, June 11th will be given a dividend of $0.054 per share. This represents a yield of 29.0%. The ex-dividend date is Thursday, June 11th.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.